Tamoxifen retinopathy. A case series of clinical and functional data;Tamoxifen-retinopathie. Eine fallserie von klinischen und funktionelle daten

Ophthalmologe

Volumn 105, Issue 6, 2008, Pages 544-549

  Ritter, C ^a   Renner, A B ^a   Wachtlin, J ^a   Bechrakis, N E ^a   Krause, L ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Colour vision; ERG; Retinopathy; Tamoxifen; Visual Field

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAMOXIFEN;

AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COLOR VISION DEFECT; CORNEA OPACITY; CRYSTALLIZATION; DISEASE COURSE; DRUG EFFECT; ELECTRORETINOGRAPHY; FEMALE; HUMAN; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA; RETINA DISEASE; RETROSPECTIVE STUDY; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COLOR VISION DEFECTS; CORNEAL OPACITY; CRYSTALLIZATION; DISEASE PROGRESSION; ELECTRORETINOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; RETINA; RETINAL DISEASES; RETROSPECTIVE STUDIES; TAMOXIFEN; TOMOGRAPHY, OPTICAL COHERENCE; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS;

EID: 46449098333     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-007-1677-8     Document Type: Article

References (30)

1. Alwitry A, Gardner I (2002) Tamoxifen Maculopathy. Arch Ophthalmol 120: 1402
2. Ashford A, Donev I, Tiwara R (1988) Reversible ocular toxicity related to tamoxifen therapy. Cancer 61: 33-35
3. Bentley C, Davies G, Aclimandos W (1992) Tamoxifen retinopathy: a rare but serious complication. BMJ 304: 495-496
4. Chang T, Gonder J, Ventresca M (1992) Low-dose tamoxifen retinopathy. Can J Ophthalmol 27: 148-149
5. Chern S, Danis R (1993) Retinopathy associated with low-dose tamoxifen. Am J Ophthalmol 116: 372-373
6. Cronin B, Lekich C, Bourke R (2005) Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol 26: 101-105
7. Engelke M, Tykhonova S, Zorn-Kruppa M, Diehl H (2002) Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 91: 13-21
8. Gerner E (1989) Ocular toxicity of tamoxifen. Ann Ophthalmol 21: 420-423
9. Gianni L, Panzini I, Li S et al. (2006) Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer. Cancer 106: 505-513
10. Gorin M, Day R, Costantino J et al. (1998) Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 125: 493-501
11. Griffiths M (1987) Tamoxifen retinopathy at low dosage. Am J Ophthalmol 15: 185-186
12. Gualino V, Cohen S, Delyfer M-N et al. (2005) Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol 140: 757-758
13. Heier J, Dragoo R, Enzenauer R, Waterhouse W (1994) Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 117: 772-775
14. Kaiser-Kupfer M, Lippman M (1978) Tamoxifen retinopathy. Cancer Treat Rep 62: 315-320
15. Kellner U, Kraus H, Foerster M (2000) Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction. Graefes Arch Clin Exp Ophthalmol 238: 94-97
16. Kellner U, Renner A, Tillack H (2006) Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using choroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 47: 3531-3538
17. Kuchenbecker J, Pump-Schmidt C, Olbricht S et al. (2001) Elektrophysiologische Untersuchungen bei Mammakarzinompatientinnen mit Tamoxifen-Retinopathie. Ophthalmologe 98: 81-85
18. Lazzaroni F, Scorolli L, Pizzoleo C et al. (1998) Tamoxifen retinopathy: does it really exist? Graefes Arch Clin Exp Ophthalmol 236: 669-673
19. Lee A (1998) Tamoxifen retinopathy. J Neuroophthalmol 18: 276
20. Marmor M, Holder G, Seeliger M, Yamamoto S (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108: 107-114
21. Martine M-F, Joel G, Maddalena Q-E (2006) Optical coherence tomography in tamoxifen retinopathy. Breast Cancer Res Treat 99: 117-118
22. McKeown C, Swartz M, Blom J (1981) Tamoxifen retinopathy. Br J Opthalmol 65: 177-179
23. Nayfield S, Gorin M (1996) Tamoxifen-associated eye disease: a review. J Clin Oncol 14: 1018-1026
24. Parkkari M, Paakkala A-M, Salminen L, Holli K (2003) Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand 81: 495-499
25. Pugesgaard T, Von Eyben F (1986) Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 58: 383-386
26. Renner A, Tillack H, Kraus H et al. (2005) Late onset is common in best macular dystrophy associated with VMD2 gene mutations. Ophthalmology 112: 586-592
27. Sutter E, Tran D (1992) The field topography of ERG components in man-I. The photopic luminance response. Vision Res 32: 433-446
28. Therssen R, Jansen E, Leys A et al. (1995) Screening for tamoxifen ocular toxicity: a prospective study. Eur J Ophthalmol 5: 230-234
29. Toler S (2004) Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy. Exp Biol Med 229: 607-615
30. Vinding T, Nielsen N (1983) Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol Scand 61: 45-50